IMbrave050 Trial Design: Adjuvant Therapy for Early-Stage Hepatocellular Carcinoma

Richard Finn, MD, professor of medicine at the Geffen School of Medicine at UCLA, is joined by Adam Yopp, MD, professor of surgery and chief of the Division of Surgical Oncology at UT Southwestern to discuss the evolving landscape of adjuvant treatment for early-stage hepatocellular carcinoma (HCC) and provide expert insights on the pivotal IMbrave050 trial. Dr. Yopp, a member of the IMbrave050 steering committee, breaks down the study’s design, including patient selection criteria, risk factors for recurrence, and the decision to evaluate atezolizumab plus bevacizumab in this setting.